Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19

Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19

Abstract Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Therefore, in this study, the PKs of remdesivir and its major...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryo Tamura (Author), Kei Irie (Author), Atsushi Nakagawa (Author), Hirohito Muroi (Author), Masaaki Eto (Author), Hiroaki Ikesue (Author), Nobuyuki Muroi (Author), Shoji Fukushima (Author), Keisuke Tomii (Author), Tohru Hashida (Author)
Format: Book
Published: Wiley, 2023-04-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items